User menu

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.

Bibliographic reference Westhovens, Rene ; Robles, Manuel ; Ximenes, Antonio Carlos ; Wollenhaupt, Jurgen ; Durez, Patrick ; et. al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.. In: Annals of the Rheumatic Diseases, Vol. 74, no. 3, p. 564-568 (2015)
Permanent URL http://hdl.handle.net/2078.1/156536
  1. Westhovens, Clin Exp Rheumatol, 32, 553 (2014)
  2. Davis PM, Nadler SG, Rouleau KA, Suchard SJ, 10.1186/ar1542
  3. Orencia Prescribing Information. 2013. http://packageinserts.bms.com/pi/pi_orencia.pdf (last accessed: 28 Sept 2014).
  4. Ma Ying, Lin Bi-rong, Lin Bei, Hou Sheng, Qian Wei-zhu, Li Jing, Tan Min, Ma Jian, Li Bo-hua, Wang Hao, Wen Ai-dong, Guo Ya-jun, Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis, 10.1038/aps.2009.13
  5. Emery P., Durez P., Dougados M., Legerton C. W., Becker J.-C., Vratsanos G., Genant H. K., Peterfy C., Mitra P., Overfield S., Qi K., Westhovens R., Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial), 10.1136/ard.2009.119016
  6. Arnett Frank C., Edworthy Steven M., Bloch Daniel A., Mcshane Dennis J., Fries James F., Cooper Norman S., Healey Louis A., Kaplan Stephen R., Liang Matthew H., Luthra Harvinder S., Medsger Thomas A., Mitchell Donald M., Neustadt David H., Pinals Robert S., Schaller Jane G., Sharp John T., Wilder Ronald L., Hunder Gene G., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, 10.1002/art.1780310302
  7. Emery, Ann Rheum Dis, 73 (2014)
  8. Emery, Arthritis Rheum, 65, 2689 (2013)
  9. van den Broek M., Klarenbeek N. B., Dirven L., van Schaardenburg D., Hulsmans H. M. J., Kerstens P. J. S. M., Huizinga T. W. J., Dijkmans B. A. C., Allaart C. F., Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study, 10.1136/ard.2010.147751
  10. Quinn Mark A., Conaghan Philip G., O'Connor Philip J., Karim Zunaid, Greenstein Adam, Brown Andrew, Brown Clare, Fraser Alexander, Jarret Stephen, Emery Paul, Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial, 10.1002/art.20712
  11. Kavanaugh Arthur, Fleischmann Roy M, Emery Paul, Kupper Hartmut, Redden Laura, Guerette Benoit, Santra Sourav, Smolen Josef S, Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study, 10.1136/annrheumdis-2011-201247
  12. Smolen Josef S, Nash Peter, Durez Patrick, Hall Stephen, Ilivanova Elena, Irazoque-Palazuelos Fedra, Miranda Pedro, Park Min-Chan, Pavelka Karel, Pedersen Ronald, Szumski Annette, Hammond Constance, Koenig Andrew S, Vlahos Bonnie, Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial, 10.1016/s0140-6736(12)61811-x
  13. Huizinga T. W. J., Donka T., Conaghan P. G., Martin-Mola E., Schett G., Amital H., Xavier R. M., Troum O., Bernasconi C., Dougados M., OP0042 Clinical and Radiographic Outcomes at Two Years and the Effect of Tocilizumab (TCZ) Discontinuation Following Sustained Remission in the Second Year of the Act-Ray Study, 10.1136/annrheumdis-2013-eular.247
  14. Tanaka, Clin Exp Rheumatol, 31, S22 (2013)
  15. Verschueren P., Westhovens R., Optimal care for early RA patients: the challenge of translating scientific data into clinical practice, 10.1093/rheumatology/ker131
  16. Westhovens R, Robles M, Ximenes A C, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park S-H, Genant H, Peterfy C, Becker J-C, Covucci A, Helfrick R, Bathon J, Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors, 10.1136/ard.2008.101121
  17. Tak Paul P, Rigby William, Rubbert-Roth Andrea, Peterfy Charles, van Vollenhoven Ronald F, Stohl William, Healy Emma, Hessey Eva, Reynard Mark, Shaw Tim, Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE, 10.1136/annrheumdis-2011-200170
  18. Detert Jacqueline, Bastian Hans, Listing Joachim, Weiß Anja, Wassenberg Siegfried, Liebhaber Anke, Rockwitz Karin, Alten Rieke, Krüger Klaus, Rau Rolf, Simon Christina, Gremmelsbacher Eva, Braun Tanja, Marsmann Bettina, Höhne-Zimmer Vera, Egerer Karl, Buttgereit Frank, Burmester Gerd-R, Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study, 10.1136/annrheumdis-2012-201612
  19. Breedveld Ferdinand C., Weisman Michael H., Kavanaugh Arthur F., Cohen Stanley B., Pavelka Karel, Vollenhoven Ronald van, Sharp John, Perez John L., Spencer-Green George T., , The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment, 10.1002/art.21519
  20. Smolen Josef S, Landewé Robert, Breedveld Ferdinand C, Buch Maya, Burmester Gerd, Dougados Maxime, Emery Paul, Gaujoux-Viala Cécile, Gossec Laure, Nam Jackie, Ramiro Sofia, Winthrop Kevin, de Wit Maarten, Aletaha Daniel, Betteridge Neil, Bijlsma Johannes W J, Boers Maarten, Buttgereit Frank, Combe Bernard, Cutolo Maurizio, Damjanov Nemanja, Hazes Johanna M W, Kouloumas Marios, Kvien Tore K, Mariette Xavier, Pavelka Karel, van Riel Piet L C M, Rubbert-Roth Andrea, Scholte-Voshaar Marieke, Scott David L, Sokka-Isler Tuulikki, Wong John B, van der Heijde Désirée, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, 10.1136/annrheumdis-2013-204573
  21. Singh Jasvinder A., Furst Daniel E., Bharat Aseem, Curtis Jeffrey R., Kavanaugh Arthur F., Kremer Joel M., Moreland Larry W., O'Dell James, Winthrop Kevin L., Beukelman Timothy, Bridges S. Louis, Chatham W. Winn, Paulus Harold E., Suarez-almazor Maria, Bombardier Claire, Dougados Maxime, Khanna Dinesh, King Charles M., Leong Amye L., Matteson Eric L., Schousboe John T., Moynihan Eileen, Kolba Karen S., Jain Archana, Volkmann Elizabeth R., Agrawal Harsh, Bae Sangmee, Mudano Amy S., Patkar Nivedita M., Saag Kenneth G., 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis : 2012 ACR RA Treatment Recommendations, 10.1002/acr.21641